Could a common diabetes drug shield your brain after a stroke?

NCT ID NCT07241897

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a diabetes drug called sentagliptin (a DPP4 inhibitor) can improve thinking and memory in people who have had a mild stroke and also have type 2 diabetes. About 312 participants will receive either the drug or a placebo daily for 180 days. Researchers will measure changes in cognitive tests to see if the drug reduces the risk of post-stroke cognitive impairment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sentagliptin Phosphate (a DPP4 inhibitor diabetes drug)
What this could lead to: If it works, this could point toward a new way to protect brain function after a stroke in people with diabetes.
What could go wrong: This is a Phase 3 trial, but it hasn't started yet. The drug may not improve cognition, and side effects from the medication are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus ischemic stroke type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETE MELLITUS ISCHEMIC STROKE

Contacts and locations

Locations

Department of Neurology, Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, 215004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.